About The Study: The efficacy of finerenone was consistent regardless of atrial fibrillation status in this study. New-onset atrial fibrillation was associated with a substantially higher risk of subsequent outcomes.
Corresponding Author: To contact the corresponding author, John J. V. McMurray, MD, email john.mcmurray@glasgow.ac.uk .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2025.0848)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American College of Cardiology’s Annual Scientific Session.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.0848?guestAccessKey=4d81e04e-ccb5-4549-bea3-a65bd04cb4c3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032925
JAMA Cardiology